Article Sidebar
Main Article Content
Low Circulating Levels of Omentin-1 and Irisin in Type 2 Diabetes Mellitus Patients with Metabolic-Associated Fatty Liver Disease
Main Article Content
Abstract
Background/Aims: The study analyzed the roles of circulating omentin-1 and irisin in patients with type 2 diabetes mellitus (T2DM) concomitant with metabolic-associated fatty liver disease (MAFLD).
Materials and Methods: This cross-sectional study included 80 patients with T2DM but no MAFLD, 62 patients with MAFLD but no T2DM, 50 T2DM patients having MAFLD (T2DM/MAFLD), and 80 healthy individuals.
Results: The serum levels of omentin-1 and irisin were both significantly reduced in patients with T2DM coexisting with MAFLD compared to T2DM or MAFLD patients alone. In T2DM patients, the level of omentin-1 decreased as the level of fasting plasma glucose (FPG) increased and the level of high-density lipoprotein cholesterol (HDL-C) reduced; the level of irisin decreased as the levels of FPG and fasting insulin (FINS) increased. In MAFLD patients, a lower level of omentin-1 was correlated with a lower level of HDL-C but with a greater waist-to-hip ratio (WHR), alanine aminotransferase and aspartate aminotransferase levels; a lower level of irisin was correlated with higher WHR and FINS level. In patients with T2DM coexisting with MAFLD, those with a lower level of omentin-1 were found to have a lower level of HDL-C concurrent with lower WHR and triglyceride level; and those with a lower level of irisin showed lower WHR, FPG and FINS levels. Combined evaluation of omentin-1 and irisin for diagnosing T2DM coexisting with MAFLD yielded an area under the curve of 0.943.
Conclusion: These findings suggest the assessment potential of omentin-1 and irisin for T2DM coexisting with MAFLD.
Cite this article as: Li H-Y, Zhang Y-Y, Cai X-M, Chen X. Low circulating levels of omentin-1 and irisin in type 2 diabetes mellitus patients with metabolic-associated fatty liver disease. Turk J Gastroenterol. 2025;36(7):450-458.
Article Details
References
1. Lu R, Liu Y, Hong T. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: a narrative review. Diabetes Obes Metab. 2023;25(suppl 1):13-26. [CrossRef]
2. Sezgin O, Akpınar H, Özer B, Törüner M, Bal K, Bor S. The abdominal ultrasonography results of Cappadocia cohort study of Turkey reveals high prevalence of fatty liver. Turk J Gastroenterol. 2023;34(6):652-664. [CrossRef]
3. Kapoor N, Kalra S. Metabolic-associated fatty liver disease and diabetes: a double whammy. Endocrinol Metab Clin North Am. 2023;52(3):469-484. [CrossRef]
4. Sena CM. Omentin: a key player in glucose homeostasis, atheroprotection, and anti-inflammatory potential for cardiovascular health in obesity and diabetes. Biomedicines. 2024;12(2):284. [CrossRef]
5. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655-1661. [CrossRef]
6. Zhao A, Xiao H, Zhu Y, et al. Omentin-1: a newly discovered warrior against metabolic related diseases. Expert Opin Ther Targets. 2022;26(3):275-289. [CrossRef]
7. Siegrist M, Heitkamp M, Braun I, et al. Changes of omentin-1 and chemerin during 4 weeks of lifestyle intervention and 1 year follow-up in children with obesity. Clin Nutr. 2021;40(11):5648-5654. [CrossRef]
8. Arman Y, Kirna K, Ugurlukisi B, et al. The effects of blood glucose regulation in Omentin-1 levels among diabetic patients. Exp Clin Endocrinol Diabetes. 2017;125(4):262-266. [CrossRef]
9. Salvoza N, Giraudi P, Gazzin S, et al. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies. J Transl Med. 2023;21(1):906. [CrossRef]
10. Waseem R, Shamsi A, Mohammad T, et al. FNDC5/Irisin: physiology and pathophysiology. Molecules. 2022;27(3):1118. [CrossRef]
11. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324-337. [CrossRef]
12. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014;63(2):207-217. [CrossRef]
13. Wen Y, Chen L, Lan J, Li L. Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels. Diabetol Metab Syndr. 2024;16(1):154. [CrossRef]
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69. [CrossRef]
15. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50(1):204-210. [CrossRef]
16. van de Luitgaarden IAT, Schrieks IC, De Bacquer D, et al. Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: findings from the ESC-EORP euroaspire V survey. Atherosclerosis. 2020;313:35-42. [CrossRef]
17. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209. [CrossRef]
18. Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. [CrossRef]
19. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):373-392. [CrossRef]
20. Xu J, Li M, Jiang X, et al. Omentin-1 and diabetes: more evidence but far from enough. Arch Physiol Biochem. 2024;130(6):599-605. [CrossRef]
21. Watanabe T, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R. Adipose tissue-derived Omentin-1 function and regulation. Compr Physiol. 2017;7(3):765-781. [CrossRef]
22. Alizadeh S, Mirzaei K, Mohammadi C, Keshavarz SA, Maghbooli Z. Circulating omentin-1 might be associated with metabolic health status in different phenotypes of body size. Arch Endocrinol Metab. 2017;61(6):567-574. [CrossRef]
23. Aliasghari F, Izadi A, Jabbari M, et al. Are vaspin and Omentin-1 related to insulin resistance, blood pressure and inflammation in NAFLD patients? J Med Biochem. 2018;37(4):470-475. [CrossRef]
24. Biscetti F, Nardella E, Bonadia N, et al. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease. Cardiovasc Diabetol. 2019;18(1):74. [CrossRef]
25. Jia G, Di F, Wang Q, et al. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. PLoS One. 2015;10(11):e0142808. [CrossRef]
26. Xin C, Liu J, Zhang J, et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond). 2016;40(3):443-451. [CrossRef]
27. Zhu W, Sahar NE, Javaid HMA, et al. Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2. Cells. 2021;10(12):3306. [CrossRef]
28. Batirel S, Bozaykut P, Mutlu Altundag E, Kartal Ozer N, Mantzoros CS. The effect of Irisin on antioxidant system in liver. Free Radic Biol Med. 2014;75(suppl 1):S16. [CrossRef]
29. Shanaki M, Moradi N, Emamgholipour S, Fadaei R, Poustchi H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr. 2017;11(suppl 1):S467-S472. [CrossRef]